key: cord-0703065-dmxdlfb3
authors: Detry, Sammy; Andries, Julie; Bloch, Yehudi; Gabay, Cem; Clancy, Danielle; Savvides, Savvas N.
title: Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein (IL-18BP) in inflammation and tumor immunity
date: 2022-02-10
journal: bioRxiv
DOI: 10.1101/2022.02.10.479912
sha: 05dac60859e08bb866b4bbdd929c57b1d6607b49
doc_id: 703065
cord_uid: dmxdlfb3

Human Interleukin-18 (IL-18) is an omnipresent pro-inflammatory cytokine of the IL-1 family with central roles in autoimmune and inflammatory diseases, and serving as a staple biomarker in the evaluation of inflammation in physiology and disease, including the inflammatory phase in COVID-19. The sequestration of IL-18 by its soluble decoy receptor IL-18 Binding Protein (IL-18BP) is critical to the regulation of IL-18 activity. Since an imbalance in expression and circulating levels of IL-18 is associated with disease, structural insights into how IL-18BP outcompetes binding of IL-18 by its cognate cell-surface receptors would be highly desirable. However, the structure of human IL-18BP in complex with IL-18 had remained elusive. Here, we elucidate the sequestration mechanism of human IL-18 mediated by IL-18BP based on the crystal structure of the IL-18:IL-18BP complex. These detailed structural snapshots reveal the interaction landscape leading to the ultra-high affinity of IL-18BP towards IL-18 and identify substantial differences with respect to previously characterized complexes of IL-18 with IL-18BP of viral origin. Furthermore, our structure captured a fortuitous higher-order assembly between IL-18 and IL-18BP coordinated by a disulfide-bond distal to the binding surface connecting IL-18 and IL-18BP molecule from different complexes, resulting in a novel complex with 2:2 stoichiometry. This tetrapartite assembly was found to restrain IL-18 activity more effectively than the canonical 1:1 complex. Collectively, our findings will provide a framework for innovative structure-driven therapeutic strategies and further functional interrogation of IL-18 in physiology and disease. Significance statement Elevated levels of interleukin-18 (IL-18) have long been implicated in numerous inflammatory diseases while also displaying potent anti-tumoral activities. Recent research on COVID-19 has now underscored the role of IL-18 and IL-18 binding protein (IL-18BP), a soluble receptor serving to regulate IL-18 activity, as key players in viral immunity and as promising biomarkers and predictors of disease severity. In this work, we present detailed structural insights into how human IL-18 and IL-18BP interact thereby completing the structural repertoire of IL-18 in complex with its cognate human receptors and viral decoy receptors. Our findings will support structure-based efforts to either disrupt or enhance the interactions of IL-18 with its cognate receptors for therapeutic purposes.

activity. Since an imbalance in expression and circulating levels of IL-18 is associated with disease, structural 30

insights into how IL-18BP outcompetes binding of IL-18 by its cognate cell-surface receptors would be 31 highly desirable. However, the structure of human IL-18BP in complex with IL-18 had remained elusive. 32

Here, we elucidate the sequestration mechanism of human IL-18 mediated by IL-18BP based on the crystal 33 structure of the IL-18:IL-18BP complex. These detailed structural snapshots reveal the interaction 34 landscape leading to the ultra-high affinity of IL-18BP towards IL-18 and identify substantial differences 35

with respect to previously characterized complexes of IL-18 with IL-18BP of viral origin. Furthermore, our 36 structure captured a fortuitous higher-order assembly between IL-18 and IL-18BP coordinated by a 37 disulfide-bond distal to the binding surface connecting IL-18 and IL-18BP molecule from different 38 complexes, resulting in a novel complex with 2:2 stoichiometry. This tetrapartite assembly was found to 39 restrain IL-18 activity more effectively than the canonical 1:1 complex. Collectively, our findings will provide 40 a framework for innovative structure-driven therapeutic strategies and further functional interrogation of 41 IL-18 in physiology and disease. Originally discovered in mice as Interferon-γ-inducing factor (IGIF), Interleukin-18 (IL-18) was found to 55 be a potent inducer of interferon-γ (IFN-γ) production in synergy with IL-12 upon exposure to intracellular 56 pathogens (1-3). It was subsequently cloned and identified as an 18 kDa cytokine belonging to the IL-1 57 cytokine family, and renamed to IL-18 (4) . Similar to other IL-1 family cytokines, IL-18 is expressed as an 58

inactive precursor protein that requires cleavage by caspase-1 for full biological activity (5, 6) . While 59 approximately 80% of pro-IL-18 is retained intracellularly, the rest is released by macrophages/monocytes 60 and dendritic cells after maturation by caspase-1 (7, 8). Mature IL-18 initiates signaling by establishing a 61

tripartite complex with IL-18 receptor alpha (IL-18Rα) and IL-18 receptor beta (IL-18Rβ), the latter also 62 known as IL-18 receptor accessory protein and IL-1R7. The heterodimerization of the receptors' 63 intracellular Toll/IL-1 receptor (TIR) domains triggers recruitment of the adaptor protein myeloid 64 differentiation primary response 88 (MyD88) which further activates the downstream signaling cascade 65 through IRAK-1/4, TRAF6 and NFκB (9-12). IL-18 is mainly involved in the activation of NK and T helper 1 66 (Th1) cells and IFN-γ production in response to intracellular bacteria or viruses (13, 14) . 67

Due to its highly proinflammatory and pleiotropic activity, IL-18 signaling is highly regulated at many 68 levels to prevent uncontrolled inflammation. Akin to other IL-1 family cytokines, this regulation is achieved 69 through gene regulation (15), caspase-1 activation (5, 6) and importantly, is also mediated by a soluble 70 decoy receptor (16). Once IL-18 is activated and released from immune cells, its availability is mainly 71 regulated by sequestration by IL-18 binding protein (IL-18BP), a dedicated soluble decoy receptor-like 72 protein capable of blocking the biological activity of IL-18 (17). Even though IL-18BP functions as a decoy 73 receptor, it is not homologous to any extracellular domain of the IL-18 receptors and is encoded as a 74

separate gene (18), an oddity in the cytokine field (19). However, bioinformatic approaches have proposed 75 that IL-18BP is evolutionary related to TIGIRR-1 (aka IL-1R9) and is thus regarded as a member of the IL-1 76 receptor family. In addition, sequence and functional homology lead to the identification of IL-18BP 77 orthologs in all orthopoxviruses (20, 21), including ectromelia virus (ectvIL-18BP) and Yaba-Like Disease 78

Virus (yldvIL-18BP) ( 

Human IL-18BP can be truncated to a bioactive core structure with reduced glycosylation 121   To enable structural studies of the human IL-18BP:IL-18 complex by X-ray crystallography we initially  122 considered clinical grade human IL-18BP (Tadekinig alfa) that was used in a phase 2 clinical trial to evaluate 123 the safety and efficacy of IL-18BP in adult-onset Still's disease (43). However, due to the extensive 124 glycosylation of this protein and the need to create glycan-engineered protein amenable to structural 125 studies by X-ray crystallography we produced full-length hIL-18BP in transiently transfected HEK293S 126 MGAT1 -/-cells allowing for N-linked glycosylation as Man5GlcNAc2 glycans (49) and mature hIL-18 in E. 127

coli. Using size-exclusion-chromatography (SEC) and in-line multi-angle laser light scattering (MALLS) we 128

found that full-length hIL-18BP was heavily glycosylated with nearly 50% of its mass accounted for by 129 glycans ( Figure 1A and Supplemental Table 1 ), consistent with predictions ( Figure S1A ). Furthermore, the 130 distribution of mass across the SEC-MALLS peak for full-length hIL-18BP, the diffuse electrophoretic 131 mobility of the purified protein in SDS-PAGE ( Figure 1A&B ), and large shifts in mass upon treatment with 132 endoglucanases and O-glycosidases suggested heterogeneous glycosylation. Based on our experience with 133 producing secreted glycoproteins with N-linked glycosylation and similar protein families in the HEK293T 134

and HEK293S MGAT1 -/-cell lines for structural biology (50-53), we reasoned that this most likely originates 135 from O-glycans and possible differences in N-and O-glycosylation site occupancy. Initial crystallization trials 136

using purified hIL-18BPFL:IL-18 complex containing glycan-shaved hIL-18BPFL and displaying apparent 137 stoichiometry of 1:1 as evaluated by SEC-MALLS, did not lead to candidate crystallization conditions even 138 when employing hIL-18BPFL:IL-18 complex up to 30 mg/mL. Such apparent high solubility during 139 crystallization trials was deemed to be consistent with the observed extensive and heterogeneous 140 glycosylation of hIL-18BPFL ( Figure 1A and Supplemental Table 1 ). Therefore, we sought to produce 141 alternative versions of hIL-18BP that would be more amenable to structural studies. Sequence alignment 142

of hIL-18BP with homologous viral IL-18BPs, for which structural information is available (22, 23), suggested 143 that the expected core beta-sandwich domain of hIL-18BP (residues 63-171) might be flanked by N-and C-144

terminal stretches (residues 31-62 and 170-194, respectively) bearing intrinsic disorder and the majority of 145 the predicted O-glycosylation sites ( Figure S1A and S1B). 146

To this end we produced hIL-18BP lacking the N-and/or C-terminal regions in HEK293S MGAT1 -/-147 cells. We found that only hIL-18BP truncated at the N-terminus (residues 63-194), hereafter termed hIL-148 18BPΔN, could be sufficiently produced for structural studies. SEC-MALLS analysis of hIL-18BPΔN revealed 149 the loss of 3 kDa of protein mass and 5.5 kDa of glycans ( Figure 1A and Supplemental Table 1), confirming 150 that the N-terminus of hIL-18BP is heavily glycosylated. Additional trimming of N-linked Man5GlcNAc2 151 glycans using Endoglycosidase H (Endo H) resulted in a further loss of 2.5 kDa of N-linked glycans ( Figure  152 1A, 1B). 153

We initially verified the functional activity of hIL-18BPΔN treated with Endo H (IL-18BPΔN-EH) in terms 154

of its ability to sequester hIL-18 in stoichiometric fashion and high affinity. Indeed, SEC-MALLS analysis 155

showed that hIL-18BPΔN-EH can establish a monodisperse complex with hIL-18 according to a 1:1 156 stoichiometry ( Figure 1C and Supplemental Table 1 ). Using isothermal titration calorimetry (ITC), we 157 compared the thermodynamic binding profiles and affinities of hIL-18BPFL, hIL-18BPΔN-EH, and the hIL-18 158 cognate receptor (IL-18Rα) to hIL-18 ( Figure 1D ). Our data show that hIL-18BPΔN-EH and hIL-18BPFL are 159

virtually indistinguishable from each other in their thermodynamic binding profiles and sub-nM affinities 160 towards hIL-18. In contrast and consistent with previously published data (26), human hIL-18Rα binds to 161

hIL-18 with lower affinity (KD=4.7 nM) than hIL-18BP. However, the binary complex affinity measured here 162 is markedly higher than previously reported affinities (KD~60 nM) (26) by surface plasmon resonance. 163

Finally, we interrogated the biological activity of hIL-18BPΔN-EH by using the hIL-18-responsive 164 macrophage cell line, KG-1, the activity of which is manifested by NFκB signaling and pro-inflammatory 165 cytokine and chemokine production (54). In this context, we measured the amount IL-8 as secreted from 166

KG-1 cells upon hIL-18 stimulation, and found that both hIL-18BPFL and hIL-18BPΔN-EH displays comparable 167 inhibitory activities. ( Figure 1E ). 168

Structural mimicry underlies the sequestration of human IL-18 by IL-18BP 169

Structural insights into the sequestration of human IL-18 by its cognate decoy receptor IL-18BP had 170 remained elusive despite the growing importance of IL-18BP in physiology and disease. Using the truncated 171

and glycan-shaved hIL-18BPΔN-EH we purified crystallization-grade hIL-18: hIL-18BPΔN-EH complex and 172

determined the crystal structure of the complex to 1.8 Å resolution by molecular replacement using crystal 173 structure of ectromelia poxvirus IL-18 binding protein (ectvIL-18BP) (23) (pdb 3f62) as a search model 174 ( Figure 2A , Table 1 ). Crystallographic refinement and the quality of the ensuing electron density maps were 175 enhanced after correcting the X-ray data for data anisotropy using the STARANISO server (55). The crystal 176 asymmetric unit contains one copy of the 1:1 complex and reveals how hIL-18BP uses the side of its h-type 177

immunoglobulin β-sandwich fold to bind the β-trefoil structure hIL-18 ( Figure 2A ). hIL-18BP harbors two 178 internal disulfide bridges connecting strands A and B (Cys86-Cys150), and B and F (Cys64-Cys89). In 179 addition, three predicted N-glycan sites are occupied by an N-Acetylglucosamine residue (GlcNAc) at 180 residues Asn79, Asn103 and Asn147. Our model for hIL-18BP starts at the beginning of the hIL-18BPΔN 181 construct, i.e. Gln63, however no density was observed past Ala170 in the crystal solvent channels, 182 consistent with the predicted disorder of the C-terminal tail ( Figure 2C , Figure S1B ). Human IL-18 features 183

its signature β-trefoil fold and closely resembles the structure of unbound hIL-18 (pdb 3wo2) (all-atom 184 r.m.s.d.=1.8 Å). Structure-based sequence alignments of human IL-18BP and structural superpositions 185 against the two structurally characterized viral IL-18BPs, ectromelia virus IL-18BP (ectvIL-18BP) and yaba-186 like disease virus disease IL-18BP (yldvIL-18BP), and domain 3 of hIL-18Rα (hIL-18RαD3) establish the strong 187 conservation of the adopted fold, albeit with major variations in the CD loop mediating hIL-18 binding and 188 AB loop ( Figure 2B , Figure 2C , Figure 2D ). Importantly, these analyses reveal that structural mimicry and 189 direct steric competition underlie the sequestration of human hIL-18 by hIL-18BP ( Figure 2C ). 190

Specifically, human IL-18BP covers the top of the hIL-18 β-barrel with one side of its β-sandwich scaffold 191

composed of strands C, G and F and is slightly inclined to enable protrusion of loops FG and BC into the 192 barrel. Additionally, residues from the CD loop and D strand mediate important interactions on the other 193 side of the sheet (Figure 2A ). In light of the plethora of structural information on human/viral IL-18BPs and 194

human IL-18Rα in complex with hIL-18, curation and comparison of the observed interaction interfaces to 195

distil key structure-function insights presents with considerable challenges. At the same time, annotation 196 of amino acid positions that have been interrogated by mutagenesis would also be desirable. Together, 197 such analyses could lead to a rationale for the exquisitely efficient sequestration of hIL-18 by hIL-18BP and 198 might further fuel protein engineering approaches to modulate this sequestration potential. Therefore, we 199 sought to develop a representation scheme that would allow effective parallel comparison of all structural 200 data available together with mutagenesis data ( Figure 3B ). The binding interface can be subdivided into 201 three sites: Site A consists of complementary hydrophobic patches on both hIL-18 and hIL-18BP. Sites B 202

and C each engage a phenylalanine on hIL-18BP, Phe106 and Phe95 respectively, to protrude into a 203

hydrophobic cavity on hIL-18 sealed by salt bridges and hydrogen-binding interactions ( Figure 3A ). 204

Sequence alignments of hIL-18BP orthologs among vertebrates ( Figure S2A ) allows mapping of highly 205

conserved residues on the surface of hIL-18BP that mediate sequestration of hIL-18, and shows that this 206 region of hIL-18BP is the most conserved compared to any other part of the decoy receptor ( Figure S2B ).

This suggests that the observed human IL-18BP:IL-18 complex can serve as a structural representative for 208 all such complexes across species. When comparing the interface of human IL-18BP with its viral 209 counterparts, these phenylalanine residues are largely conserved, with the exception of yldvIL-18BP, which 210

contains a threonine instead of phenylalanine at site B. The most striking difference is the lack of salt bridges 211

in viral IL-18BPs at site C. Conversely, human IL-18Rα does form these salt bridges but lacks the 212 phenylalanine residues protruding into the hydrophobic cavity of hIL-18, while also lacking another 213 hydrophobic substitute. At site B, hIL-18Rα also lacks the phenylalanine residue, but substitutes it for a 214 methionine to fill the hydrophobic pocket ( Figure 3B ). Overall, site A is very similar for all interfaces, with 215 mainly conservative substitutions of key interacting residues. The absence of these phenylalanine residues 216 may explain the higher affinity of human IL-18BP to IL-18 than its receptor. Similar to IL-18Rα, but in 217

contrast to the viral IL-18BPs, human IL-18BP exploits additional interactions via two side-chain-to-main-218

chain hydrogen bonds at site A. 219 220 A disulfide-linked interaction site mediates a novel higher-order IL-18:IL-18BP complex 221

An intriguing feature of the IL-18-IL-18BP complex concerns an unexpected disulfide bridge between Cys74 222 of hIL-18 in the canonical IL-18:IL-18BP complex and Cys131 of IL-18BP participating in a symmetry-related 223

complex. This results in a covalent tetrameric assembly with a 2:2 stoichiometry and twofold symmetry 224

( Figure 4A ). We note that such higher-order assembly was not observed in the preparatory stages of pre-225 crystallization samples as assessed by SEC-MALLS or SDS-PAGE ( Figure 1B and 1C) . However, the sample 226 was concentrated to 30 mg/ml prior to crystallization. To verify whether such a higher order complex 227 originated during this final protein concentration step, the concentrated sample was diluted back to 0.5 228 mg/ml and analyzed by SDS-PAGE and SEC-MALLS. SDS-PAGE shows a band at ∼38 kDa which can be 229

resolved to the constituent protein components upon the addition of the reducing agent DTT prior to 230

loading the sample, indicating the presence of a disulfide linked dimer ( Figure 4B ). We confirmed by mass 231 spectrometry that both hIL-18 and hIL-18BP were present in this disulfide linked protein adduct, verifying 232 a heterodimer as opposed to a homodimer of either. Additionally, SEC-MALLS shows that more than 90% 233

of the previously concentrated sample now exists as a tetramer of 74 kDa, rather than the expected 234 canonical IL-18:IL-18BP complex of 37 kDa ( Figure 4C ). Protein conjugate analysis of SEC-MALLS data 235

validated the presence of both hIL-18BP and hIL-18 in the complex with a 2:2 stoichiometry, as any other 236

combination of proteins and their glycans would not be compatible with their respective molecular masses. 237

Interestingly, in the structure of unbound hIL-18 and when in complex with its decoy and signaling 238 receptors, the cysteine involved in the observed novel disulfide bond with IL-18BP is part of a 310 helix and 239

is not surface exposed ( Figure 4A , left panel). This region in inbound IL-18 is rather amphipathic in terms of 240 physicochemical properties and interacts with several detergent molecules (CHAPS) in pdb 3wo2 (26) . 241

Thus, to participate in the observed disulfide bond, the cysteine has flipped outwards and is accompanied 242 by a structural rearrangement thereby disrupting the helical structure ( Figure 4A , left panel). Interestingly, 243

an ensemble of structural models of IL-18 determined by NMR has shown this helix to be very flexible (56), 244

which would favor such dynamics. We note that for the reported crystals structure of hIL-18 complexed 245

with ectvIL-18BP and yldvIL-18BP (pdb 3f62 and 4eee respectively), all free cysteines were mutated to 246 serine, thereby excluding the possibility of such a disulfide linkage, although this particular helix/loop 247 segment was not modelled due to its apparent flexibility. Surrounding the cysteine disulfide bridge is a 248 novel interface mediated by the beta strands E, B, D and D' of the opposite side of the beta-sandwich 249 compared to the canonical interface and is maintained by a several hydrophobic residues on both 250

molecules. 251

Because this hetero-tetramer was only initially observed with IL-18BPΔN-EH lacking the N-terminal and N-252

glycans, we also investigated if a similar higher-order complex could be formed with IL-18BPFL or 253 endogenously glycosylated IL-18BPΔN. Full-length IL-18BP was complexed with IL-18, concentrated to 0.5 254 mg/mL and analyzed by SEC-MALLS. No tetrameric complex was observed using IL-18BPFL, either in its 255 glycosylated or deglycosylated form, suggesting that removal of the N-terminal segment of IL-18BP 256

promotes the formation of this hetero-tetrameric complex ( Figure 4C ). We note that Cys51 is part of the 257 truncated and likely pairs up with Cys131 in the full-length protein, thus preventing heterotetramer 258

formation. Endogenously glycosylated IL-18BPΔN, without Endo H treatment, also formed a tetrameric 259 complex with IL-18 at high concentrations, albeit at a lower rate than IL-18BPΔN-EH ( Figure 4D) . the tetrameric assembly restrained IL-18 activity more effectively than the dimeric complex, resulting in 267 less inflammatory cytokine production from KG-1 cells ( Figure 4E ). 268

Over the past two decades and in the absence of an experimentally determined structure for the human 271

IL troughs on each side of the interface, supplemented with two side-chain-to-main-chain hydrogen bonds.

Comparing the structure of hIL-18BP with its viral orthologs confirms that this large hydrophobic patch on 284 site A is highly conserved. yldvIL-18BP contains some additional hydrophobic residues (Ile78 and Leu80) on 285

the DE loop interacting with hIL-18 (Leu 5 and Glu6) at the perimeter of the interface. In all other structures, 286 except yldvIL-18BP, this loop is constrained as an additional βD' strand. On each side of the hydrophobic 287 patch, a phenylalanine on hIL-18BP is tightly inserted inside hydrophobic cavities on hIL-18 and additionally 288 locked down by salt bridges (Site B and C, Figure 3B ). Mutating either phenylalanine residues to alanine 289 reduces the ultra-high picomolar affinity of hIL-18BP down to low-nanomolar affinity (22, 23, 57).

Mutations of the corresponding residues in viral IL-18BPs have a similar effect, highlighting the importance 291 of these specific residues for binding. Interestingly, in hIL-18Rα the corresponding residue is either 292 substituted by methionine (Site B) or completely lacking (Site C), although site B is flanked by additional 293 hydrophobic residues residing on hIL18Rα's longer CD' loop. The absence of these seemingly critical 294

phenylalanine residues may, in part, explain the higher affinity of hIL-18BP to IL-18 than its receptor. 295

Similarly, mutating Glu108 and Glu106 on hIL-18BP involved in the salt bridges at Site B accordingly resulted 296

in a lower affinity, as well as mutating Lys53 on hIL-18 which is located on the other end of the salt bridges 297

(58, 59). Mutations in Site C particularly have not been reported, because in both viral structures the 298 corresponding residues (Glu48 in ectvIL-18BP and His51 in yldvIL-18BP) are not involved in salt bridge 299

formation. Overall, it is clear that hIL-18BP utilizes a unique constellation of key residues, contributing to 300 ultra-high affinity binding to IL-18, however further investigation is required to determine binding hotspots 301 important for this interaction. Whether or not the lower affinity of viral IL-18BPs is actually advantageous 302 or disadvantageous for their function is unclear. 303

Unexpectedly, we observed a higher order assembly of IL-18 and IL-18BP in our crystallographic 304 model, coordinated by an otherwise buried cysteine in IL-18, disrupting an alpha helix in the process. Using 305 SEC-MALLS and mass spectrometry, we confirmed the formation of a hetero-tetramer, consisting of two 306 complexes of IL-18:IL-18BP, with an additional interaction interface distal to the canonical binding site of 307 IL-18BP. Interestingly, this hetero-tetrameric complex restrained IL-18 activity more effectively than the 308 canonical dimeric 1:1 complex. Given that high concentrations and removal of the N-terminal region appear 309

to be required, it is likely not biologically relevant. However, this fortuitous observation suggests that this 310 interface may be amenable to further engineering to increase the sequestration potency of IL-18BP, 311 possibly in combination with domains 1 and 2 of IL-18Rα. It brings to light plasticity in IL-18, the possible 312 reactivity of Cys131 in IL-18BP, and the possible utilization of a hydrophobic patch at opposite ends to the 313 IL-18:IL-18BP interface to create a new interaction interface. An analogous yet distinct bivalence has been 314 observed in viral yldvIL-18BP. This ortholog lacks a highly conserved phenylalanine residue in site B, 315

however it compensates for this by forming a 2:2 complex with IL-18, driven by disulfide-linked IL-18BP 316 homodimerization (23) . However, it is important to note that the 2:2 hetero-tetrameric complex seen here 317

for human IL-18BP engages a separate interface, and is driven by an additional interaction with IL-18 318

cytokine. 319

The structural model presented here will facilitate further the structure-driven development of 320 novel therapeutics to either disrupt or mimic hIL-18BP binding. The Avi-His6-tag was cleaved by caspase-3 (produced in-house) and the glycans were trimmed by EndoH 406 Finally, wells were washed three times, followed by addition of 50 ml TMB substrate solution. The reaction 449 was stopped with 30 ml of 2M sulfuric acid and absorbance was read at 450 nm on an ELISA plate reader 450 (Fluostar). All cytokine assays were carried out using triplicate samples from each culture. 451

All sequence alignments were performed by Clustal Omega (71). Structural alignments were performed in 453

Swiss-PdbViewer (72). Glycan prediction were performed using NetNGlyc (73) and NetOGlyc servers (74). 454

Protein disorder was predicted using IUPred (75). Sequence alignments were visualized by ESPript (76). 455

Protein structures were visualized in PyMOL (77, 78). Interaction interface was inferred using the PISA 456 server (79). M Sodium cacodylate trihydrate pH 6.5, 18% w/v Polyethylene glycol 8000) was optimized by varying pH 466 (6.2-7.1) and PEG concentration (12%-27%). Crystals obtained from the optimization screen were used for 467 seeding new plates, finally yielding single crystals. These crystals were cryoprotected in mother liquor 468 supplemented with 20% glucose prior to cryo-cooling in liquid nitrogen. Diffraction data was initially 469 collected under cryogenic conditions at a synchrotron radiation source, namely beamline PETRA III in 470

Hamburg. 471

The diffraction data were integrated using XDS (80) and were treated for anisotropy using the 472 STARANISO server (55). Initial phases were determined by maximum-likelihood molecular replacement in Commun. 5 background, residues with similarity are colored orange. Groups of high similarity residues are surrounded 714 by a blue box. 715 Values in parentheses correspond to the highest resolution shell (1.87 -1.80). 729 **10% of reflections in R-free set 

High-level induction of gamma interferon with 494 various mitogens in mice pretreated with Propionibacterium acnes

Cellular mechanisms in in vivo 497 production of gamma interferon induced by lipopolysaccharide in mice infected with 498 Mycobacterium bovis BCG

Endotoxin-induced serum factor that 500 stimulates gamma interferon production

Cloning of the cDNA for human IFN-gamma-inducing factor

Escherichia coli, and studies on the biologic activities of the protein

Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-505 gamma production

Activation of interferon-gamma inducing factor mediated by interleukin-1beta 507 converting enzyme. Science (80-. )

Overview of the IL-1 family in innate inflammation and acquired immunity

Proteolytic Processing of Interleukin-1 Family 511 Cytokines: Variations on a Common Theme

MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling 513 pathways

MyD88: An adapter that recruits IRAK to the 515 IL-1 receptor complex

TRAF6 is a signal transducer for 517 interleukin-1

Interleukin-1β (IL-1β) processing pathway

Interleukin-18

Interleukin-18 and IL-18 binding protein. Front. 522 Immunol

Regulation of IL-18 (IFN-gamma-524 inducing factor) gene expression

Interleukin-1 and Related Cytokines in the 526 Regulation of Inflammation and Immunity

Interleukin-18 Binding Protein: A Novel Modulator of the Th1 Cytokine Response

Interleukin-18, more than a Th1 cytokine

Mechanisms of immunomodulation by mammalian and viral decoy 532 receptors: insights from structures

A Poxvirus Protein That Binds to and Inactivates IL-18, and Inhibits NK Cell 536 Response

Structural basis for antagonism of human interleukin 18 538 by poxvirus interleukin 18-binding protein

A unique bivalent binding and inhibition 540 mechanism by the yatapoxvirus interleukin 18 binding protein

A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive 542 decrease of free IL-18

Orthopoxvirus Il-18 binding proteins: Affinities and antagonist 544 activities

Clinical and biological effects of recombinant human interleukin-18 593 administered by intravenous infusion to patients with advanced cancer

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously 596 untreated metastatic melanoma

A dose-escalation study of recombinant human Lnterleukin-18 using two 598 different schedules of administration in patients with cancer

Structure and function in rhodopsin: high level 601 expression of a synthetic bovine opsin gene and its mutants in stable mammalian cell lines

Allosteric competitive inactivation of hematopoietic CSF-1 signaling by the viral 604 decoy receptor BARF1

Structure and Assembly Mechanism of the Signaling Complex Mediated by Human 606 CSF-1

Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23

Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1

Structural basis of GM-CSF and IL-2 sequestration by the viral decoy receptor GIF

Functional role played by the glycosylphosphatidylinositol 612 anchor glycan of CD48 in interleukin-18-induced interferon-γ production

The structure and binding mode of interleukin-18

Determination of the Functional Epitopes of Human Interleukin-18-binding 618 Protein by Site-directed Mutagenesis

Structural requirements of six naturally occurring isoforms of the IL-18 binding 620 protein to inhibit IL-18

Identification of amino acid residues critical for biological activity in human 622 interleukin-18

IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias

Cytokine release syndrome in a patient with colorectal cancer after vaccination with 626 BNT162b2

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, 628 and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of 631 severity and predictors of death

IL-18 and infections: Is there a role for targeted therapies?

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-635 cytokine interventions

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

A time-and cost-efficient system for high-level protein 639 production in mammalian cells

Structure and function in rhodopsin : High-641 level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-642 HEK293S stable mammalian cell line

High-precision, automated integration of multiple isothermal titration 644 calorimetric thermograms: New features of NITPIC

SEDPHAT -A platform for global ITC analysis and global multi-method analysis of 646 molecular interactions

The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids 648 Res

SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative 650 protein modeling

Prediction of N-glycosylation sites in human proteins

Precision mapping of the human O-GalNAc glycoproteome through SimpleCell 653 technology

IUPred: web server for the prediction of intrinsically 655 unstructured regions of proteins based on estimated energy content

Deciphering key features in protein structures with the new ENDscript server. 658

The PyMOL Molecular Graphics System

The PyMOL Molecular Graphics System, Version~1

Inference of Macromolecular Assemblies from Crystalline State

Phaser crystallographic software

Features and development of Coot

PHENIX: a comprehensive Python-based system for macromolecular structure 669 solution

Site-specific mutations in the mature form of human IL-18 with enhanced 673 biological activity and decreased neutralization by IL-18 binding protein

hIL-18BPΔN-EH complex prior to crystallization allow accurate stoichiometry 684 determination (A) & (C) Full lines show the SEC retention profile of samples (∼0.5-1 mg/ml) detected by 685 UV (left axis, 280 nm). Interrupted lines show the molecular weights in kDa of the sample over the course 686 of the SEC peak, split up by protein conjugate analysis in total (dashed and dotted), protein (dashed) and 687 glycan

Bar plot of IL-8 levels in conditioned media after hIL-18 stimulation in presence or absence of hIL-18BPFL 689 or IL-18BPΔN-EH. Recombinant IL-18 was pre-incubated for 1 h at 37 o C with the indicated concentrations of 690 full-length IL-18BP or IL-18BPΔN-EH. KG-1 cells were left untreated (UT) or stimulated with IL-18 (purple) (0.5 691 nM final concentration) +/-IL-18BP (teal and orange), as indicated. After 18 h, IL-8 concentration in cell 692 culture supernatants was measured by ELISA

hIL-18BPFL and hIL-18BPΔN-EH shows 694 recombinantly produced hIL-18 and hIL-18BPΔN-EH are both functionally competent. Bottom plots show the 695 raw baseline-subtracted thermograms while top plots show integrated heats (blue dots) with fitted 696 isotherm (red line). Diagrams in the isotherm plot show which protein was in the cell or syringe and what 697 the

yldvIL-716 18BP (purple, pdb 4eee(23)) and hIL-18Rα (dark blue, pdb 3WO4(26)) aligned to hIL-18BPΔN-EH. Only notable 717 differences on the level of secondary structures are colored accordingly, while stretches that align to hIL-718 18BPΔN-EH are left grey. Structural alignment of these structures shows that the core h-type Ig-fold is 719 maintained with some strand and loop alterations, with an average all atom RMSD of 2.5 Å. Compared to 720 human IL-18BP, ectv-and yldvIL-18BP have a shorter AB loop

D) Cartoon representation of crystal structures of hIL-18BPΔN-EH (orange, pdb 7al7), ectvIL-18BP (teal, pdb 723 3f62(22)), yldvIL-18BP (purple, pdb 4eee(23)) and hIL-18Rα (dark blue, pdb 3WO4(26)) aligned to hIL

Structures of hIL-18BPΔN-EH shown consist out of the bottom half of the beta-736 sandwich, with the top half and non-interacting loops hidden. Top left, bottom left, and bottom right panels 737 show zoomed-in views of the three main interaction sites B, A and C respectively, with hIL-18BPΔN-EH and 738 hIL-18 shown in cartoon representation with a transparent surface overlay for hIL-18. Key residues are 739 shown in stick representation colored by element

Diagrams show simplified interactions at site A, B and C of hIL-18 (purple) with hIL-18BP (orange), viral 742 ectvIL-18BP and ylvdIL-18BP (cyan), and domain 3 of hIL-18Ra (dark blue). The interaction between hIL-18 743 and hIL-18BP consists of 3 sites: A, B and C. Site A consists of interlocking rows of hydrophobic residues

Site B consist of a phenylalanine flanked by hydrophobic side chains supplemented with two salt bridges

Notable differences with ectvIL-18BP and yldvIL-18BP are missing salt bridges at site C, 747 even though a capable side chain is present for ectvIL-18BP. ylvdIL-18BP also has a threonine replacing the 748 phenylalanine at site B. hIL-18Ra-D3 does have the salt bridges at site C, but is lacking the phenylalanine 749 with no substitution, while at site B, the phenylalanine is replaced with a methionine. Residues marked with 750 a red asterisk have been reported to have reduced affinity after certain mutations. Residues marked with 751 a green asterisk have been reported to not be affected by certain mutations

Middle panel shows an overview of the assembly using cartoon representation of 760 hIL-18 (purple or teal) and hIL-18BPΔN-EH (orange) with the disulfide links involved shown in yellow stick 761 representation. Left panel shows a zoomed-in view with an aligned overlay of the 310 α-helix from a crystal 762 structure of unbound hIL-18 (teal, pdb 3wo2(26)) showing disruption of the helix upon formation of the 763 disulfide link. The right panel displays the novel interface surrounding the disulfide link with hIL-18 shown 764 in surface representation (purple, pdb 7al7) and hIL-18BPΔN-EH in cartoon representation (orange

reducing (DTT) or no agents added. 768 Reduction results in dissociation of the otherwise disulfide-linked tetramer. 769 (C) SEC-MALLS analysis of hIL-18, hIL-18BPΔN-EH and hIL-18:hIL-18BPΔN-EH complex before and after 770 concentration to 30 mg/ml prior to and diluting back to 0.5 mg/ml. Line plots show the SEC retention profile 771 of samples detected by UV (left axis)

hIL-18BPFL complex sample after concentration to 775 30 mg/ml and diluting back to 0.5 mg/ml. Line plots show the SEC retention profile of samples detected by 776 UV (left axis)

pg/mL) in conditioned media after human IL-18 stimulation in presence or 780 absence of dimeric or tetrameric IL-18BPΔN-EH:IL-18 complex. Recombinant IL-18 was pre-incubated for 1 h 781 at 37 o C with the indicated concentrations of full-length IL-18BP or IL-18BPΔN-EH. KG-1 cells were left 782 untreated (UT) or stimulated with IL-18 (purple) (0.5 nM final concentration) +/-IL-18BP (teal and orange), 783 as indicated

Supplementary Information for Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein (IL-18BP) in inflammation and tumor immunity

Julie Andries 1,2,# , Yehudi Bloch 1,2 , Cem Gabay 3 , Danielle Clancy 1,2 , Savvas N. Savvides 1,2,* 1 Unit for Structural Biology

Unit for Structural Biology

Color scale above the sequence of hIL-18BP represents conservation levels determined by ConSurf 6 , with high conservation colored in orange, low conservation levels in teal and white in between. The same scale is used in panel B. (B) Surface representation of hIL-18BPΔN-EH colored by residue conservation. hIL-18 binding to hIL-18BPΔN-EH is either displayed in cartoon representation

The EMBL-EBI search and sequence analysis tools APIs in 2019

Deciphering key features in protein structures with the new ENDscript server

Prediction of N-glycosylation sites in human proteins

Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology

IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content

ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules

Figures S1 to S2 Tables SI References